HR 4065 117th Congress House Health Administrative law and regulatory procedures Congressional oversight Department of Health and Human Services Digestive and metabolic diseases Drug therapy Government studies and investigations Health care costs and insurance Health care coverage and access Health care quality Health facilities and institutions Health promotion and preventive care Health technology, devices, supplies Medicaid Medical research Medical tests and diagnostic methods Medicare Minority health Organ and tissue donation and transplantation State and local government operations

Chronic Kidney Disease Improvement in Research and Treatment Act of 2021

Introduced: November 18, 2021 Introduced by: Sewell, Terri A. Democratic · Alabama See on congress.gov

Everywhere this bill has been 4 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Jun 23, 2021

Referred to the Subcommittee on Health.

Jun 22, 2021

Referred to the Subcommittee on Health.

Jun 22, 2021

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Jun 22, 2021

Introduced in House

Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

Plain-English summary Congressional Research Service

Chronic Kidney Disease Improvement in Research and Treatment Act of 2021

This bill modifies provisions relating to Medicare coverage of treatments for chronic kidney disease.

Specifically, the bill expands the Medicare annual wellness visit to include chronic kidney disease screening and allows certain Medicare beneficiaries who have End Stage Renal Disease (ESRD) to enroll in Medicare supplemental policies. It also (1) provides for alternative payment methodologies for certain new drugs, biologics, and devices that are renal dialysis services; (2) revises quality measures; (3) establishes an incentive payment methodology; and (4) increases access to kidney disease education services.

The bill also extends the coordination period (from 30 months to 42 months) during which private health insurers may serve as the primary payers for Medicare beneficiaries with ESRD.

What's happening now June 23, 2021

Referred to the Subcommittee on Health.

Related & companion bills 2

Bill text 1 version

Introduced in House Formatted Text PDF Formatted XML

Source documents hosted by congress.gov.

Committees of jurisdiction 4

Energy and Commerce Committee
House of Representatives
Health Subcommittee
House of Representatives · subcommittee of Ways and Means Committee
Health Subcommittee
House of Representatives · subcommittee of Energy and Commerce Committee
Ways and Means Committee
House of Representatives

Cosponsors 7

Tlaib, Rashida

Michigan · May 12, 2022

O'Halleran, Tom

· Nov 18, 2021

Cohen, Steve

Tennessee · Sep 28, 2021

Fitzpatrick, Brian K.

Pennsylvania · Jul 16, 2021

JOHNSON, EDDIE

· Jul 16, 2021

Plaskett, Stacey E.

Virgin Islands · Jul 16, 2021

Buchanan, Vern

Florida · Jun 22, 2021

Cite this page click to expand

APA

U.S. Congress. (2026). H.R. 4065: Chronic Kidney Disease Improvement in Research and Treatment Act of 2021. 117th Congress. Open America. https://openamerica.io/bill/117-HR-4065/

MLA

"H.R. 4065: Chronic Kidney Disease Improvement in Research and Treatment Act of 2021." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-4065/.

Bluebook (legal)

H.R. 4065, 117th Cong. (2026), https://openamerica.io/bill/117-HR-4065/.

Markdown link

[H.R. 4065: Chronic Kidney Disease Improvement in Research and Treatment Act of 2021](https://openamerica.io/bill/117-HR-4065/)